Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

AVROBIO logo

About AVROBIO Stock (NASDAQ:AVRO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.40
$18.24
52-Week Range
N/A
Volume
206,800 shs
Average Volume
269,831 shs
Market Capitalization
$62.85 million
P/E Ratio
2.03
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AVRO Stock News Headlines

NVIDIA's Worst Nightmare?
$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible.tc pixel
L'action TECX atteint un sommet sur 52 semaines à 53,41$
See More Headlines

AVRO Stock Analysis - Frequently Asked Questions

AVROBIO, Inc. (NASDAQ:AVRO) issued its earnings results on Thursday, November, 4th. The company reported ($9.00) earnings per share for the quarter, hitting the consensus estimate of ($9.00).

AVROBIO shares reverse split on the morning of Thursday, June 20th 2024.The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE).

Company Calendar

Last Earnings
11/04/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVRO
CIK
1681087
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.69
Trailing P/E Ratio
2.03
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-50.52%
Return on Assets
-47.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.17
Quick Ratio
26.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.13 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
44,890,000
Free Float
40,764,000
Market Cap
$62.85 million
Optionable
Optionable
Beta
1.23
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:AVRO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners